title: Pharmacokinetic profiles of nevirapine and indinavir in various fractions of seminal plasma.
abstract: Limited data are available on antiretroviral drug concentrations in seminal plasma during a dosing interval. Further, since human ejaculate is composed of fluids originating from the testes, the seminal vesicles, and the prostate, all having different physiological characteristics, drug concentrations in total seminal plasma do not necessarily reflect concentrations in the separate compartments. Five human immunodeficiency virus type 1-infected patients on nevirapine (NVP; 200 mg twice a day [b.i.d.]) and/or indinavir (IDV; 800 mg b.i.d. with ritonavir, 100 mg b.i.d.) regimens used a split ejaculate technique to separate seminal plasma in two fractions, representing fluids from the testes and prostate (first fraction) and fluids from the seminal vesicles (second fraction). Split-ejaculate samples were provided at 0, 2, 5, and 8 h after drug ingestion, on separate days after 3 days of sexual abstinence. NVP and IDV showed time-dependent concentrations in seminal plasma, with peak concentrations in both fractions at 2 and 2 to 5 h, respectively, after drug ingestion. The NVP concentrations were not significantly different between the first and second fractions of the ejaculate at all time points measured and were in the therapeutic range, except for the predose concentration in two patients. The median (range) predose IDV concentrations in the first and second fractions of the ejaculate were 448 (353 to 1,015) ng/ml and 527 (240 to 849) ng/ml, respectively (P = 0.7). In conclusion, NVP and IDV concentrations in seminal plasma are dependent on the time after drug ingestion. Furthermore, our data suggest that NVP and IDV achieve therapeutic concentrations in both the testes and prostate and the seminal vesicles throughout the dosing interval.
authors.affiliation: National AIDS Therapy Evaluation Center, Department of Internal Medicine, University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands.
authors.forename: R M
authors.initials: RM
authors.lastname: van Praag
authors.forename: S
authors.initials: S
authors.lastname: Repping
authors.forename: J W
authors.initials: JW
authors.lastname: de Vries
authors.forename: J M
authors.initials: JM
authors.lastname: Lange
authors.forename: R M
authors.initials: RM
authors.lastname: Hoetelmans
authors.forename: J M
authors.initials: JM
authors.lastname: Prins
mesh_terms: D019380:Anti-HIV Agents / Q000097:blood / Q000493:pharmacokinetics*; D015658:HIV Infections / Q000378:metabolism*; D015497:HIV-1 / Q000187:drug effects; D006801:Humans; D019469:Indinavir / Q000097:blood / Q000493:pharmacokinetics*; D008297:Male; D019829:Nevirapine / Q000097:blood / Q000493:pharmacokinetics*; D012661:Semen / Q000378:metabolism*
chemical_list: D019380:Anti-HIV Agents; D019469:Indinavir; D019829:Nevirapine